Kurajoh, Masafumi
Fukumoto, Shinya
Akari, Seigo
Murase, Takayo
Nakamura, Takashi
Takahashi, Kanae
Yoshida, Hisako
Nakatani, Shinya
Tsuda, Akihiro
Morioka, Tomoaki
Mori, Katsuhito
Imanishi, Yasuo
Hirata, Kazuto
Emoto, Masanori
Funding for this research was provided by:
Sanwa Kagaku Kenkyusho
Gout Research Foundation
Taisho Toyama Pharmaceutical Company
Takeda Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Chugai Pharmaceutical Co
Astellas Pharma
Osaka City University (OCU) Strategic Research Grant
Japan Society for the Promotion of Science (18K11132)
Article History
Received: 16 April 2021
Accepted: 18 April 2022
First Online: 18 June 2022
Competing interests
: Seigo Akari, Takayo Murase, and Takashi Nakamura of Sanwa Kagaku Kenkyusho Co. Ltd. developed the plasma XOR activity assay used in this study and also performed measurements of that activity. Their involvement does not alter our adherence regarding sharing of data and materials. The other authors have no conflicts of interest to declare.